Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial.

Thierry PrazuckRenaud VerdonGwenaël Le MoalFaïza AjanaLouis BernardSimon SunderMariam Roncato-SaberanDiane PonscarmeManuel EtienneJean-Paul ViardThierry PasdeloupIuliana DarasteanuGilles PialouxArnaud de la BlanchardièreVéronique Avettand-FènoëlJean-Jacques Parienti Laurent Hocquelouxnull null

Published in: The Journal of antimicrobial chemotherapy (2021)

Although non-inferiority was shown, simplification to tenofovir disoproxil fumarate/emtricitabine should not be used for most PLHIV because of a low risk of VF with resistance.

Keyphrases

antiretroviral therapy
hiv infected
open label
hiv infected patients
phase iii
hiv positive
human immunodeficiency virus
clinical trial
phase ii
study protocol
hiv aids
hepatitis c virus
circulating tumor
single molecule
hiv testing
squamous cell carcinoma
radiation therapy
nucleic acid